75 related articles for article (PubMed ID: 19927314)
1. Reduced CRYL1 expression in hepatocellular carcinoma confers cell growth advantages and correlates with adverse patient prognosis.
Cheng IK; Ching AK; Chan TC; Chan AW; Wong CK; Choy KW; Kwan M; Lai PB; Wong N
J Pathol; 2010 Feb; 220(3):348-60. PubMed ID: 19927314
[TBL] [Abstract][Full Text] [Related]
2. Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest.
Gho JW; Ip WK; Chan KY; Law PT; Lai PB; Wong N
Cancer Res; 2008 Aug; 68(16):6743-51. PubMed ID: 18701499
[TBL] [Abstract][Full Text] [Related]
3. Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma.
Hellerbrand C; Mühlbauer M; Wallner S; Schuierer M; Behrmann I; Bataille F; Weiss T; Schölmerich J; Bosserhoff AK
Carcinogenesis; 2006 Jan; 27(1):64-72. PubMed ID: 16081515
[TBL] [Abstract][Full Text] [Related]
4. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
[TBL] [Abstract][Full Text] [Related]
5. The clinicopathological significance of BUBR1 overexpression in hepatocellular carcinoma.
Liu AW; Cai J; Zhao XL; Xu AM; Fu HQ; Nian H; Zhang SH
J Clin Pathol; 2009 Nov; 62(11):1003-8. PubMed ID: 19861558
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma.
Shih YL; Shyu RY; Hsieh CB; Lai HC; Liu KY; Chu TY; Lin YW
Cancer; 2006 Aug; 107(3):579-90. PubMed ID: 16795071
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of ZBP-89 and its prognostic significance in hepatocellular carcinoma.
Zhang CZ; Cao Y; Yun JP; Chen GG; Lai PB
Histopathology; 2012 Jun; 60(7):1114-24. PubMed ID: 22372401
[TBL] [Abstract][Full Text] [Related]
8. Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma.
Lu CY; Hsieh SY; Lu YJ; Wu CS; Chen LC; Lo SJ; Wu CT; Chou MY; Huang TH; Chang YS
Genes Chromosomes Cancer; 2009 Dec; 48(12):1057-68. PubMed ID: 19760608
[TBL] [Abstract][Full Text] [Related]
9. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma.
Lee YC; Pan HW; Peng SY; Lai PL; Kuo WS; Ou YH; Hsu HC
Eur J Cancer; 2007 Mar; 43(4):736-44. PubMed ID: 17267202
[TBL] [Abstract][Full Text] [Related]
11. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis.
Mao TL; Chu JS; Jeng YM; Lai PL; Hsu HC
J Pathol; 2001 Jan; 193(1):95-101. PubMed ID: 11169521
[TBL] [Abstract][Full Text] [Related]
12. Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma.
Morinaga S; Nakamura Y; Ishiwa N; Yoshikawa T; Noguchi Y; Yamamoto Y; Rino Y; Imada T; Takanashi Y; Akaike M; Sugimasa Y; Takemiya S
Oncol Rep; 2004 Dec; 12(6):1189-94. PubMed ID: 15547736
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma.
Fang F; Luo LB; Tao YM; Wu F; Yang LY
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):409-16. PubMed ID: 19208663
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of Wiskott-Aldrich syndrome protein family verprolin-homologous protein 2 correlated with poor prognosis of hepatocellular carcinoma.
Yang LY; Tao YM; Ou DP; Wang W; Chang ZG; Wu F
Clin Cancer Res; 2006 Oct; 12(19):5673-9. PubMed ID: 17020969
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma.
Huang J; Zhang X; Tang Q; Zhang F; Li Y; Feng Z; Zhu J
J Clin Pathol; 2011 Apr; 64(4):343-8. PubMed ID: 21270061
[TBL] [Abstract][Full Text] [Related]
16. Alterations of the fragile histidine triad gene in hepatitis C virus-associated hepatocellular carcinoma.
Zekri AR; Bahnassy AA; Hafez M; El-Shehaby AM; Sherif GM; Khaled HM; Zakhary N
J Gastroenterol Hepatol; 2005 Jan; 20(1):87-94. PubMed ID: 15610452
[TBL] [Abstract][Full Text] [Related]
17. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma.
Che Y; Ye F; Xu R; Qing H; Wang X; Yin F; Cui M; Burstein D; Jiang B; Zhang DY
Am J Pathol; 2012 May; 180(5):1798-807. PubMed ID: 22429965
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
20. Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma.
Ip WK; Lai PB; Wong NL; Sy SM; Beheshti B; Squire JA; Wong N
Cancer Lett; 2007 Jun; 250(2):284-91. PubMed ID: 17126992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
